Insider · CIK 0001967163
Patel Anish
cooofficer
Files at ELVN (Enliven Therapeutics, Inc.). First filing Oct 22, 2024, latest Mar 11, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $996k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 26Weak | sell 410b5-1 | ELVN Enliven Therapeutics, Inc. | $143k | 6,667 | -2% | - | |
| 19Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | $146k | 6,667 | -2% | - | |
| 34Weak | sell 210b5-1 | ELVN Enliven Therapeutics, Inc. | $686k | 28,367 | -131% | - | |
| 15Weak | sell 610b5-1 | ELVN Enliven Therapeutics, Inc. | $21k | 716 | -0% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,667 | $21.44 | $143k | 323,310 | Mar 11, 2025 |
| Feb 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,667 | $21.93 | $146k | 329,977 | Feb 10, 2025 |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +171,000 | $0.00 | $0 | 171,000 | Feb 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +10,700 | $1.12 | $12k | 10,700 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +2,000 | $2.48 | $4,960 | 12,700 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +9,000 | $2.48 | $22k | 21,700 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,260 | $24.15 | $489k | 1,440 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,440 | $24.56 | $35k | 0 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,577 | $24.17 | $159k | 336,734 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -90 | $24.60 | $2,214 | 336,644 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -10,700 | $0.00 | $0 | 67 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 827 | Jan 10, 2025 |
| Jan 7, 2025 | ELVN Enliven Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -9,000 | $0.00 | $0 | 44,342 | Jan 10, 2025 |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -716 | $30.00 | $21k | 343,311 | Oct 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.